Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
暂无分享,去创建一个
P. Thall | E. Estey | H. Kantarjian | J. Cortes | S. Pierce | F. Giles | Xuemei Wang | S. Pierce | J. Cortes | M. Beran | S. O'brien | X. Wang | S. O’Brien | P. Thall